Colin Shannon Professional Profile
Colin Shannon has served as Chief Executive Officer at PRA Health Sciences (formally PRA International) since January 1, 2010. He was appointed President and Chief Operating Officer in May 2007. Prior to joining PRA, Mr. Shannon was employed by Pharmaceutical Product Development Inc. (PPD) for 12 years in key executive positions including Executive Vice President of Global Clinical Operations. He joined PPD in 1995 and served for four years as Chief Operating Officer for its European operations. His other roles at PPD included Vice President and Chief Financial and Administrative Officer for International Operations as well as Executive Director and Chief Financial Officer for Europe.
Prior to PPD, Mr. Shannon had more than 15 years of experience in a variety of financial and accounting positions in the utility and multimedia industries. Mr. Shannon holds a Master’s in Business Administration from City University in London and is a Fellow Member of the Chartered Association of Accountants.
During Mr. Shannon’s tenure at PRA Health Sciences, the company was named “Best CRO” in 2013 for the 3rd Annual BioPharma Asia Industry Awards. PRA was also named the U.S. Clinical Researcher of the Year’s “Clinical Company of the Year” in 2012 and 2013. From 2007 to present, Mr. Shannon has overseen extensive company growth including the addition of more than 7,000 employees and a 14% organic revenue increase.
Under Mr. Shannon’s leadership, PRA Health Sciences has significantly expanded its capabilities through a series of strategic acquisitions. The company strengthened its coverage of China and created a joint venture with the leading clinical development firm in China, forming WuXiPRA. PRA also bolstered its international capabilities by acquiring ClinStar, the premier provider of CRO services in Russia and Eastern Europe. The acquisition of RPS, the pioneer of the Embedded Solutions model™, allowed PRA to enhance its ability to offer a more comprehensive breadth of services across all segments of the biopharmaceutical industry. In 2013, PRA purchased CRI Lifetree, which augmented its existing Phase I and bioanalytical capabilities, solidifying PRA as the most comprehensive, high-end Phase I organization in the world. PRA’s decision to change its name to PRA Health Sciences in 2014 reflected the culmination of a series of strategic decisions to support and enhance the company’s commitment to the future of clinical development.